Sernova Biotherapeutics Inc.

Dr. Douglas Loe, Leede Financial Inc. (1/23/26) "SVA's partnered initiatives could drive Cell Pouch activity in 2026."

Dr. Douglas Loe, Leede Financial Inc. (1/9/26) "We expect AT-1501 data from SVA's Cell Pouch study later this year."

Dr. Douglas Loe, Leede Financial Inc. (10/3/25) "SVA is converting CA$13.3M in legacy accounts payable into equity."

Dr. Douglas Loe, Leede Financial Inc. (7/10/25) "SVA announced an alliance with Eledon Pharmaceuticals."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (7/9/25) "In its Phase 1/2 T1D trial, SVA will evaluate Eledon's tegoprubart."

Dr. Andre Uddin, Research Capital Corporation (6/16/25) "Positive Cohort C data could be a value inflection point for SVA."

Dr. Douglas Loe, Leede Financial Inc. (5/16/25) "SVA is achieving positive results with both Cell Pouch configurations."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (5/14/25) "SVA's interim data indicate the T1D trial is on track to succeed."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (4/22/25) "We see opportunity for SVA and Cell Pouch where VX-264 came up short."

Dr. Douglas Loe, Leede Financial Inc. (4/17/25) "SVA just raised CA$4M in new debt capital."

Dr. Douglas Loe, Leede Financial Inc. (4/4/25) "The clinical risk for SVA's Cell Pouch itself is essentially nil at this stage."

Dr. Douglas Loe, Leede Financial Inc. (3/31/25) "The end of Vertex's VX-264 program is on balance positive for SVA."

Dr. Douglas Loe, Leede Financial Inc. (3/3/25) "SVA may proceed with Phase 1 testing of Cell Pouch in thyroid disease."

Dr. Douglas Loe, Leede Financial Inc. (2/3/25) "SVA filed an IND for testing of its Cell Pouch in thyroid disease."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (2/3/25) "SVA's Cell Pouch could become a 'pipeline in a device.'"

Dr. Douglas Loe, Leede Financial Inc. (1/31/25) "SVA added U.S. executive Ross Haghighat to its board."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (1/22/25) "We are encouraged by new data from SVA's trial of Cell Pouch in T1D."

Dr. Douglas Loe, Leede Financial Inc. (12/6/24) "SVA enters into new alliance in Saudi Arabia for Type 1 diabetes."

Dr. Douglas Loe, Leede Financial Inc. (11/15/24) "SVA partner, Evotec, received a formal bid to be acquired by Halozyme."

Dr. Douglas Loe, Leede Financial Inc. (11/6/24) "SVA's partnership landscape should expand."

Dr. Douglas Loe, Leede Financial Inc. (9/20/24) "SVA's new board member has tech commercialization experience."

Clive Maund, CliveMaund.com (9/12/24) "SVA is considered to be very undervalued here."

Dr. Douglas Loe, Leede Financial Inc. (9/12/24) "SV's Phase 1 update is positive to the Cell Pouch's medical prospects."

Dr. Joseph Pantginis, H.C. Wainwright & Co. (9/12/24) "Efficacy in SV's Cell Pouch trial in type 1 diabetes deepens."

Stefan Quenneville, Ventum Capital Markets (9/12/24) "SV appointed Executive Chairman Jonathan Rigby as CEO."

Viveve Medical Inc.

Brian Marckx, Zacks Small-Cap Research (5/17/18) "VIVE's Q1/18 total revenue was $3.7M, up 22% year over year."

Jeff Cohen, Ladenburg Thalmann (5/11/18) "VIVE expanded the commercial sales force in Q1/18 to a total of 42."

Anthony Vendetti, Maxim Group (5/11/18) "VIVE reported Q1/18 revenue of $3.7M, up 21.6% year over year."

Brian Marckx, Zacks Small-Cap Research (3/28/18) "VIVE has now grown revenue sequentially for 13 consecutive quarters."

Jeff Cohen, Ladenburg Thalmann (3/19/18) "VIVE announced FDA approval of its IDE application for VIVEVE II."

Jefferson Research (3/16/18) "VIVE is showing strong cash flow quality and earnings quality."

Anthony Vendetti, Maxim Group (3/16/18) "VIVE's Q4/17 revenue of $5.1M was up 108% year over year."

Jeff Cohen, Ladenburg Thalmann (3/16/18) "VIVE's cash as of Q4/17 was $20.7M."

Anthony Vendetti, Maxim Group (2/12/18) "The net capital raised is sufficient to fund VIVE through 2019E."

Brian Marckx, Zacks Small-Cap Research (2/7/18) "VIVE expects to forge ahead with stress urinary incontinence studies."

Jeff Cohen, Ladenburg Thalmann (2/2/18) "VIVE intends to expand its CMRF platform into a new market."

Brian Marckx, Zacks Small-Cap Research (1/4/18) "VIVE's 2018 revenue guidance was largely in line with our estimate."

Jeff Cohen, Ladenburg Thalmann (1/4/18) "VIVE's revenue of $15.3M for FY17 beat our estimate of $15.2M."

Anthony Vendetti, Maxim Group (1/4/18) "VIVE's preliminary Q4/17 revenue of ~$5.1M was up 108% YOY."

Jefferson Research (12/22/17) "VIVE is showing strong cash flow quality and earnings quality."

Brian Marckx, Zacks Small-Cap Research (12/8/17) "Subanalysis data provide confidence in success of VIVE's VIVEVE II."

Brian Marckx, Zacks Small-Cap Research (11/15/17) "Q3/17 was, by far, VIVE's strongest, with 47 U.S. console placements."

Jeff Cohen, Ladenburg Thalmann (11/9/17) "VIVE raised its outlook for 2017 revenues from $14M to $15–16M."

Anthony Vendetti, Maxim Group (11/9/17) "We would continue to be buyers of VIVE after an in-line Q3/17."

Brian Marckx, Zacks Small-Cap Research (10/20/17) "VIVE's Q3/17 revenue of ~$4.1M compares to our $3.7M estimate."

Anthony Vendetti, Maxim Group (10/18/17) "VIVE's Q3/17 revenue of approximately $4.1M was up roughly 122% YOY."

Reliq Health Technologies Inc.

Chris Parry, Equity Guru (10/5/17) "RHT now has 1000 patients into their system from two customers, and expect somewhere between 2000 and 2500 to be added next month."

Clive Maund, CliveMaund.com (9/22/17) "RHT is a pioneer in technologies that allow hospital patients to return home sooner."

Michael Berger, TalkMarkets (9/6/17) "August was a banner month for RHT and these developments have the firm positioned for incremental growth."

Viveve Medical Inc.

Jeff Cohen, Ladenburg Thalmann (8/11/17) "We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."

Anthony Vendetti, Maxim Group (8/11/17) "We believe VIVE's Phase 3 trial is on track for a readout of data in mid-2019."

Brian Marckx, Zacks Equity Research (7/11/17) "VIVE is off to a strong start, we expect domestic sales to accelerate throughout 2017."

Anthony Vendetti, Maxim Group (5/12/17) "We continue to be buyers of VIVE following its seventh consecutive quarter of double-digit revenue growth driven by a successful launch of the U.S. commercialization coupled with reaffirmed guidance."

Jeff Cohen, Ladenburg Thalmann (5/12/17) "VIVE has plans for dual pathways into the U.S. marketplace of which the first has been approved."

Gregory Chodaczek, B. Riley Securities (5/12/17) "VIVE reported revenue of $3.04MM, $265,000 higher than we had expected."

Josh Jennings, Cowen & Co. (5/3/17) "We initiate with an Outperform on VIVE."

Brian Marckx, Zacks Small-Cap Research (2/21/17) "VIVE set new records in Q4/16 in console and treatment tip sales."

Anthony Vendetti, Maxim Group (2/17/17) "We believe VIVE's focus on attaining additional regulatory clearances, supporting its global distribution partners, expanding its direct sales force, and investing in market awareness, should position it for continued growth."

Brian Marckx, Zacks Equity Research (1/30/17) "VIVE recently crossed what we characterize as a major milestone with the entry of the Viveve System into the U.S. market and the recent announcement last week that they have begun deployment of their initial domestic sales force."

Brian Marckx, Zacks Equity Research (11/16/16) "VIVE's marketing study, along with data from previous studies and the recent significantly beefed-up distribution is expected to help accelerate the roll-out of the Viveve System."

Jeff Cohen, Ladenburg Thalmann (11/14/16) "VIVE's commercial activities continue to gain traction in a variety of worldwide markets with a current base of 162 systems."

CapitalCube (11/14/16) "VIVE's gross margins widened from 28.60% to 37.37% compared to the same period last year."

Anthony Vendetti, Maxim Group (11/11/16) "We view VIVE's recent regulatory clearances as significant milestones (S. Korea, Brazil and the U.S.), as approval in these countries represents large market opportunities."

Brian Marckx, Zacks Equity Research (10/13/16) "VIVE continues to make substantive progress towards their quest to commercialize the Viveve System in the U.S."

Jeff Cohen, Ladenburg Thalmann (10/7/16)

The Life Sciences Report Interview with Anthony Vendetti (10/5/16) "Viveve has the technology, it's putting together a worldwide distribution network, and it has the management team to execute."

Jeff Cohen, Ladenburg Thalmann (9/20/16) "VIVE's Three human studies have been performed with extremely encouraging results."

3D Signatures Inc.

James West, Midas Letter (9/7/16) "DXD is a diagnostic technology platform that analyzes changes in telomere structures within DNA to determine aspects and characteristics of deadly diseases like cancer and Alzheimer's Disease."

Viveve Medical Inc.

Anthony Vendetti, Maxim Group (8/12/16) "We would continue to be buyers of VIVE following its fourth consecutive quarter of double-digit revenue growth."

Charles Haff, Craig-Hallum Capital (8/8/16) "Given the enormous size of the market opportunity, the elegance of VIVE's solution, and a strong management team that we believe can execute on the opportunity."

Brian Marckx, Zacks Equity Research (6/22/16)

Anthony Vendetti, Maxim Group (6/21/16) "VIVE is well-positioned to gain regulatory clearances in additional countries, which should lead to the Viveve System gaining further traction."

Brian Marckx, Zacks Equity Research (6/15/16)

Anthony Vendetti, Maxim Group (4/27/16) "The positive results of VIVE's VIVEVE I clinical trial builds upon the two previous clinical studies conducted in the U.S. and Japan."

Gregory Chodaczek, Sterne Agee (4/22/16)

Reliq Health Technologies Inc.

Nick Hodge, Outsider Club (3/28/16) "MSD is pursuing a roll-up strategy whereby it will grow through acquisitions that could lead it to several million in revenue in fairly short order."

Viveve Medical Inc.

Anthony Vendetti, Maxim Group (3/9/16) "VIVE's MonaLisa Touch continues to be a critical driver of top-line growth."

Aethlon Medical Inc.

Brian Marckx, Zacks Small-Cap Research (2/26/16) "AEMD's management has been very resilient and successful in pursuing high potential opportunities."

Nobilis Health Corp.

Charles Haff, BioTuesdays (2/16/16) "We like that HLTH's management and board members have made open market purchases in recent weeks."

Aethlon Medical Inc.

Brian Marckx, Zacks Small-Cap Research (2/5/16) "AEMD continues to make substantive positive progress on several fronts."